Let’s talk about Pfizer Inc. (PFE), a major player in the Drug Manufacturers – General industry with a substantial market capitalization of $146.98 billion. When we look at a company like Pfizer, the big question on everyone’s mind is always: Is the current stock price truly reflective of its value? And perhaps more importantly, is Pfizer positioned for exciting growth ahead?
As of December 2025, Pfizer’s stock is trading at $25.85. What’s interesting right off the bat is that PFE is showing some positive momentum, comfortably trading above both its 50-day and 200-day moving averages. That’s usually a good sign for short-term sentiment.
However, it’s not all sunshine and rainbows. While analysts are generally optimistic with a 1-year price target of $28.91, implying an 11.8% potential upside, there’s also a model-driven forecast suggesting a potential -9.2% downside to $23.48. This divergence, coupled with an annualized volatility of 20.3%, hints at potentially wide price swings ahead. Pfizer’s financial narrative is a bit of a mixed bag; it boasts strong profitability with an impressive 15.65% profit margin, but it’s also grappling with a recent -21.30% year-over-year contraction in earnings. This makes for a compelling analysis.
What’s Inside This PFE Stock Analysis?
We’re here to give you a comprehensive breakdown of PFE’s stock, moving beyond just the raw numbers. Our goal is to equip you with the insights needed to make a truly informed investment decision.
- Is now a good time to buy PFE? Technically, things look neutral, with the Relative Strength Index (RSI) at 52.0. Fundamentally, the picture seems solid, especially when we consider debt levels and growth metrics.
- Can Pfizer’s core operations drive future growth? Future success will largely hinge on its performance in the Drug Manufacturers – General sector and its ability to navigate intense competitive pressures.
- What are the biggest risks for Pfizer stock? The company carries a substantial debt load of $61.94 billion, which could become a significant headwind, particularly in a higher-interest-rate environment. Plus, competition is fierce, coming from both established pharmaceutical giants and innovative new entrants.
Most stock analyses either drown you in jargon or oversimplify things with a generic “buy” recommendation. That’s not what we’re about here. We aim to provide clear, actionable information that benefits you, whether you’re a long-term investor or a short-term trader. So, is Pfizer Inc. the right investment to help your portfolio thrive?
Or are there hidden issues to be mindful of? Let’s dive into the data and find out.
PFE Stock Key Metrics and Forecast Summary
Here’s a quick snapshot of Pfizer’s current market standing and what the immediate future might hold, based on recent data as of December 2025.
| Metric Category | Metric | Value | Comment |
|---|---|---|---|
| Current Price | Live Market Price | $25.85 | As of December 2025 |
| Price Targets & Forecasts | 1-Month Forecast | $25.85 | 📈 +0.0% |
| 1-Year Forecast (Model) | $23.48 | 📉 -9.2% Potential Downside | |
| Analyst Mean Target | $28.91 | 📈 +11.8% Potential Upside | |
| Trend & Momentum | Trend | 🚀 ▲ Bullish | Price > SMA 50/200 |
| RSI (14-day) | 52.0 | Neutral ⚖️ | |
| MACD | -0.02 | ➡️ Neutral Trend | |
| Key Technical Levels | Above SMA 50 | ✅ $25.03 | Strong support indicator |
| Above SMA 200 | ✅ $24.28 | Long-term bullish signal | |
| 52-Week Range | $20.92 – $27.69 | 📏 Moderate range | |
| Volatility | Volatility (30d Ann.) | 20.3% | 🌊 Moderate price swings |
| Beta (vs. Market) | 0.42x | 🛡️ Low Sensitivity | |
| Green Days (30d) | 15/30 (50%) | 🟡 Balanced performance | |
| Ownership | Institutional Ownership | 67.51% | 🏛️ Significant institutional backing |
| Short % of Float | 2.45% | 😐 Moderate bearish bets |
Currently, PFE’s stock is trading at $25.85. Looking at the technicals, we see a bullish pattern emerging because the price is holding strong relative to both the 50-day ($25.03) and 200-day ($24.28) moving averages. This indicates that the stock has been gaining some solid momentum recently. However, the Relative Strength Index (RSI) sits at 52.0, suggesting a neutral stance—it’s neither overbought nor oversold. The MACD indicator also shows a neutral trend, meaning we might see some minor pullbacks before any significant upward movement continues.
Over the past year, PFE has traded within a range of $20.92 to $27.69. This tells us a couple of things: investor sentiment has been quite mixed, and the current price is right in the middle, implying that huge swings are less likely unless there’s a major market catalyst. Analysts are forecasting modest growth, with a 1-year target of $23.48 (-9.2%) from one model and an average consensus target of $28.91 (+11.8%) from Wall Street. With 67.51% institutional ownership and a relatively low short interest of 2.45%, it appears many large investors are banking on Pfizer’s long-term potential rather than expecting a decline.
Detailed PFE Forecast Table
Here’s a detailed monthly breakdown of the price forecast for Pfizer Inc. (PFE), which model projections place in an overall range of approximately $15.92 to $35.81 over the coming year. This table outlines the projected price bands, the potential return on investment (ROI) compared to the current price, and the corresponding model signal for each period.
| Month (Period) | Min. Price | Avg. Price | Max. Price | Potential ROI vs Current ($25.85) | Model Signal |
|---|---|---|---|---|---|
| 2025-12 | $25.85 | $25.85 | $25.85 | ● 0.0% | Hold/Neutral |
| 2026-01 | $22.97 | $24.98 | $26.57 | ▼ -3.4% | Consider Short |
| 2026-02 | $21.90 | $24.18 | $26.32 | ▼ -6.5% | Consider Short |
| 2026-03 | $20.64 | $23.40 | $27.29 | ▼ -9.5% | Consider Short |
| 2026-04 | $20.27 | $23.40 | $27.41 | ▼ -9.5% | Consider Short |
| 2026-05 | $19.54 | $23.52 | $29.09 | ▼ -9.0% | Consider Short |
| 2026-06 | $19.92 | $23.78 | $29.65 | ▼ -8.0% | Consider Short |
| 2026-07 | $19.28 | $23.92 | $31.54 | ▼ -7.4% | Consider Short |
| 2026-08 | $19.38 | $24.29 | $32.92 | ▼ -6.1% | Consider Short |
| 2026-09 | $17.86 | $24.17 | $33.59 | ▼ -6.5% | Consider Short |
| 2026-10 | $15.92 | $23.57 | $34.20 | ▼ -8.8% | Consider Short |
| 2026-11 | $16.06 | $23.48 | $34.20 | ▼ -9.2% | Consider Short |
| 2026-12 | $16.08 | $24.08 | $35.81 | ▼ -6.8% | Consider Short |
Over the forecast horizon, from December 2025 to December 2026, the model projects PFE’s price to fluctuate between approximately $15.92 and $35.81. It’s noteworthy that the forecast uncertainty appears quite steady, with the overall price range showing little change over this period. This consistency suggests that while price movement is expected, the degree of unpredictability might remain relatively stable.
Just a friendly reminder: these forecasts are generated by sophisticated models and inherently carry a degree of uncertainty. They can shift significantly with new data or evolving market dynamics. Remember, future stock prices are never guaranteed.
Pfizer Inc. (PFE) Company Profile and Business Overview
Let’s get to know Pfizer Inc. a bit better. Understanding its core business and market positioning provides essential context for our analysis.
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Drug Manufacturers – General |
| Market Cap | $146.98 B |
| Employees | 81,000 |
| Website | https://www.pfizer.com |
Business Overview
Pfizer Inc. is a global biopharmaceutical powerhouse. The company is actively involved in discovering, developing, manufacturing, marketing, distributing, and selling a wide range of biopharmaceutical products across the United States and internationally. It’s a massive operation with a significant impact on global health.
Their portfolio is incredibly diverse, covering various therapeutic areas. For cardiovascular and migraine, they offer well-known brands like Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family. In infectious diseases, they address unmet medical needs with products such as the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba.
Of course, we can’t forget their significant contributions to COVID-19 prevention and treatment with Comirnaty and Paxlovid, alongside potential future mRNA and antiviral products. Pfizer also provides biosimilars for chronic immune and inflammatory diseases (Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, Cibinqo), and medicines for amyloidosis, hemophilia, endocrine diseases, and sickle cell disease (Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, Genotropin).
Their sterile injectable and anti-infective medicines include Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga. Furthermore, Pfizer is deeply involved in biologics, small molecules, immunotherapies, and biosimilars under brands like Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna. Beyond drug development, the company also engages in contract manufacturing.
Pfizer serves a broad spectrum of clients, including wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, and integrated delivery systems. They also have notable collaboration agreements with industry giants like Bristol-Myers Squibb Company, Astellas Pharma US, Inc., Merck KGaA, and BioNTech SE. Founded in 1849, Pfizer Inc. remains headquartered in New York, New York, a testament to its enduring legacy in the pharmaceutical world.
PFE Total Valuation Insights
While the market recognizes Pfizer Inc. as a pivotal player in the Drug Manufacturers – General industry with a substantial $146.98 billion market cap, its enterprise value (EV) tells a slightly different story. The EV stands at a higher $193.93 billion, with $46.95 billion of that value attributed to its debt. This suggests that while investors are confident about Pfizer’s future earnings power, the considerable debt load is a factor to keep in mind.
When we look at Pfizer’s valuation ratios, they paint an interesting picture. Trading at 3.09x revenue and 7.94x EBITDA, the company’s valuation reflects its strong market position and valuable brand assets. This implies that investors are willing to pay a premium for a quality business, but it also means there might be less room for error if performance falters. The upcoming 2026-01-23 ex-dividend date is a good reminder that Pfizer continues to reward its shareholders while also investing for future growth. Essentially, you’re investing in quality, and quality often comes with a higher price tag.
| Metric | Value |
|---|---|
| Market Cap | $146.98 B |
| Enterprise Value | $193.93 B |
| EV/Revenue (TTM) | 3.09x |
| EV/EBITDA (TTM) | 7.94x |
| Ex-Dividend Date | 2026-01-23 |
PFE Share Statistics and Ownership Landscape
Let’s delve into Pfizer’s share statistics to understand the ownership structure and potential market dynamics. Nearly all of the company’s 6 billion shares are publicly available as float, meaning a significant portion isn’t locked up. This high float usually allows investors to trade the stock without causing overly dramatic price shifts. However, it’s also worth noting that a large float means the company could issue more shares in the future, potentially diluting the value of existing stock.
Interestingly, executives and major shareholders own a very small portion of the company, just 0.08%. This might suggest they don’t have a substantial amount of “skin in the game” if the company faces challenges. On the flip side, the level of institutional ownership is quite healthy, coming in at 67.51%. This strong institutional backing often provides a degree of stability and confidence in the stock, as large funds typically conduct extensive due diligence.
Now, let’s consider the impact of short interest on the market. With 139 million shares currently shorted, representing 2.45% of the float, it suggests that bearish sentiment isn’t overwhelmingly strong. While a sharp increase in short interest could signal growing investor doubt, the current low level generally means that the market feels more confident, and the risks of significant price swings from sudden short-covering activities are reduced. You can often find detailed filings on institutional ownership and insider transactions on the SEC Edgar database.
| Metric | Value |
|---|---|
| Shares Outstanding | 6 B |
| Implied Shares Outstanding | 6 B |
| Shares Float | 6 B |
| Insider Ownership | 0.08% |
| Institutional Ownership | 67.51% |
| Shares Short | 139 M |
| Short Ratio (Days To Cover) | 1.50x |
| Short % of Float | 2.45% |
| Shares Short (Prior Month) | 127 M |
| Short Date | 2025-11-28 |
PFE Valuation Metrics: Unpacking How the Market Prices Pfizer
When evaluating Pfizer’s stock, its valuation multiples offer crucial insights into how the market currently prices the company relative to its earnings, sales, and assets. Pfizer’s Trailing P/E ratio stands at 15.03x, while its Forward P/E is notably lower at 8.44x. This significant difference in P/E ratios often suggests that analysts are expecting strong earnings growth ahead, making the forward valuation look quite attractive. For investors, this could signal a potential opportunity if those growth expectations materialize.
Beyond earnings, Pfizer’s Price/Sales ratio of 2.34x and Price/Book ratio of 1.58x also warrant attention. These metrics indicate that the company trades at multiples that reflect its market positioning within the pharmaceutical sector. From an enterprise value perspective, the EV/Revenue ratio of 3.09x suggests a reasonable valuation based on its top-line performance, while an EV/EBITDA multiple of 7.94x points to a fair valuation relative to its earnings before interest, taxes, depreciation, and amortization. Collectively, these valuation metrics provide a comprehensive view of Pfizer’s current standing in the market.
| Metric | Value |
|---|---|
| Trailing P/E | 15.03x |
| Forward P/E | 8.44x |
| Price/Sales (TTM) | $2.34 |
| Price/Book (MRQ) | $1.58 |
| EV/Revenue (TTM) | 3.09x |
| EV/EBITDA (TTM) | 7.94x |
Pfizer’s Financial Health: A Robust Foundation
Pfizer’s financial health appears quite robust, showcasing several key strengths that investors will appreciate. Its Return on Equity (ROE) of 10.60% and Return on Assets (ROA) of 5.19% reflect highly efficient capital utilization, which is a positive sign for any company, especially one of Pfizer’s scale. This efficiency suggests that management is doing a good job of generating profits from the capital and assets at its disposal.
The company’s Debt/Equity ratio of 0.67x, with $61.94 billion in debt offset by $14.99 billion in cash, indicates a manageable debt load. This debt is likely being used to fuel operations and strategic growth initiatives without overburdening the balance sheet. Even with this debt, Pfizer’s ability to generate $13.08 billion in operating cash flow (TTM) proves that its core business can consistently produce cash, which is a significant strength and a reassuring indicator of operational stability.
Looking at liquidity, the Current Ratio of 1.28x and Quick Ratio of 0.90x demonstrate a solid position, indicating that Pfizer can comfortably cover its short-term liabilities. Furthermore, the impressive $14.30 billion in levered free cash flow suggests the company can generate substantial cash for shareholders even after meeting all its financial obligations. You can always check the latest financial statements for PFE on Yahoo Finance.
| Metric | Value |
|---|---|
| Return on Equity (ROE TTM) | 10.60% |
| Return on Assets (ROA TTM) | 5.19% |
| Debt/Equity (MRQ) | 0.67x |
| Total Cash (MRQ) | $14.99 B |
| Total Debt (MRQ) | $61.94 B |
| Current Ratio (MRQ) | 1.28x |
| Quick Ratio (MRQ) | 0.90x |
| Operating Cash Flow (TTM) | $13.08 B |
| Levered Free Cash Flow (TTM) | $14.30 B |
Pfizer’s Financial Efficiency: Optimizing Operations
When it comes to financial efficiency, Pfizer presents a nuanced picture. Its Asset Turnover of 0.29x suggests that the company generates $0.29 in revenue for every dollar of assets. This indicates a relatively lower efficiency in utilizing its assets, which might be an area for potential improvement. Meanwhile, the Inventory Turnover of 1.65x shows that Pfizer slowly sells and replaces its inventory roughly 1.6 times annually, translating to approximately 221.2 Days Inventory Outstanding.
On the collection side, a Receivables Turnover of 5.48x and 66.6 Days Sales Outstanding reflect slower collections, which could warrant closer attention from management. However, Pfizer’s Working Capital Turnover of 8.53x indicates a highly efficient use of its short-term assets to support sales. This is further supported by a Current Ratio of 1.28x, signaling adequate liquidity to manage short-term obligations.
The Cash Conversion Cycle, estimated at approximately 287.8 days (partial), suggests it takes Pfizer about 9.6 months to convert its inventory and receivables into cash. This extended cash conversion period could potentially strain working capital. Finally, the Return on Invested Capital (ROIC) of 6.45% indicates moderate capital efficiency, showing how effectively Pfizer generates returns from the capital it has invested. Overall, while Pfizer demonstrates strengths in some areas, higher asset utilization could further boost profitability. Investors should compare these figures with industry peers to assess Pfizer’s competitive positioning.
| Metric | Value |
|---|---|
| Asset Turnover (TTM) | 0.29x |
| Inventory Turnover (TTM) | 1.65x |
| Receivables Turnover (TTM) | 5.48x |
| Working Capital Turnover (TTM) | 8.53x |
| Current Ratio (MRQ) | 1.28x |
| Days Sales Outstanding | 66.6 |
| Days Inventory Outstanding | 221.2 |
| Cash Conversion Cycle | ~287.8 days (partial) |
| Return on Invested Capital (ROIC TTM) | 6.45% |
Pfizer’s Profitability and Growth: A Balanced Approach
An in-depth look at Pfizer’s margin performance reveals that the company maintains solid control over its costs and pricing strategies. The impressive 74.81% gross margin demonstrates its success in managing production costs effectively. Furthermore, the 35.28% operating margin reflects strong profitability from its core operations, indicating that Pfizer is adept at converting revenue into profit before accounting for non-operating expenses.
The 38.96% EBITDA margin is another positive sign, indicating Pfizer’s capability to generate robust cash flow from its operations before factoring in financing and tax strategies. All things considered, Pfizer is able to retain approximately 15.65 cents in net profit for every dollar of revenue generated over the last twelve months. While the business’s revenue growth is currently showing a slow rate of -5.90% year-over-year, investors should closely monitor whether this pace can be sustained without eroding those healthy profit margins.
Pfizer’s $24.46 billion in EBITDA and $46.97 billion in gross profit highlight its raw earning power. Meanwhile, the $9.80 billion in net income reveals how effectively the company converts that power into bottom-line results. These indicators suggest that Pfizer is currently prioritizing strong profitability over rapid, top-line growth. Despite healthy gross margins, there’s a notable difference between the company’s gross and net margins (74.81% vs. 15.65%). This gap is likely due to significant operating expenses, interest costs, or taxes, which are key areas for investors to monitor.
Moving forward, maintaining steady or improving margins will be critical for Pfizer. The company needs to defend its pricing power and diligently control operating costs, especially if revenue growth continues to moderate. This strategic focus will be essential for sustaining profitability in the long run.
| Metric | Value |
|---|---|
| Profit Margin (TTM) | 15.65% |
| Operating Margin (TTM) | 35.28% |
| Gross Margin (TTM) | 74.81% |
| EBITDA Margin (TTM) | 38.96% |
| Revenue (TTM) | $62.78 B |
| Quarterly Revenue Growth (YoY) | -5.90% |
| Gross Profit (TTM) | $46.97 B |
| EBITDA (TTM) | $24.46 B |
| Net Income (TTM) | $9.80 B |
| Earnings Growth (YoY) | -21.30% |
PFE Dividends and Shareholder Returns
Dividend Summary & Investor Implications for Pfizer Stock
Pfizer currently offers an attractive $1.72 annual dividend per share, which translates to a dividend yield of 6.65%. This means that for every $100 invested, shareholders would receive approximately $1.72 in dividends annually. What’s particularly noteworthy is that this yield is significantly above its 5-year average of 4.82%, making Pfizer stock appear more appealing to income-focused investors today compared to its recent historical performance.
Key Observations & Analysis:
- The payout ratio of 99.42% is quite high, indicating that Pfizer uses nearly all of its earnings to fund its dividends. While this leaves ample room for future increases or reinvestment in growth, it’s crucial for investors to check the company’s cash flow sustainability to ensure the payout remains well-supported.
- The very low trailing yield of 0.07% suggests either a very recent dividend initiation or a special, non-recurring payout in the past. This warrants further checks for consistency in dividend payments.
- Investors must own the stock before the upcoming ex-dividend date of 2026-01-23 to be eligible to receive the next dividend payment.
Investor Takeaway:
- Income Investors: The current dividend yield is compelling, but closely monitor Pfizer’s earnings and cash flow to ensure the payout remains sustainable in the long term.
- Growth Investors: Pfizer strikes a balance between returning capital to shareholders and reinvesting in the business, making it potentially suitable for a ‘growth and income’ investment strategy.
Watch For:
- Any announcements of dividend hikes, which could bring the yield closer to its historical average.
- Significant fluctuations in the stock price that would naturally alter the dividend yield.
| Metric | Value |
|---|---|
| Dividend Rate | $1.72 |
| Dividend Yield | 6.65% |
| Payout Ratio | 99.42% |
| 5 Year Average Dividend Yield | 4.82% |
| Trailing Dividend Rate | $1.70 |
| Trailing Dividend Yield | 0.07% |
| Ex-Dividend Date | 2026-01-23 |
| Last Split Date | 2020-11-17 |
| Last Split Factor | 1054:1000 |
PFE Technical Analysis: Bullish Trend Showing Signs of Slowing
As of December 2025, Pfizer (PFE) is trading at $25.85. The current trend appears bullish, but we’re starting to see signs that this momentum might be slowing down. The stock has enjoyed a notable run, gaining +0.54% in just 15 days. However, several technical indicators suggest that it might be wise for investors to exercise caution before chasing this rally. Let’s break down what the charts are telling us and how you might position yourself.
Trend Strength – Still Bullish for PFE
Pfizer is currently trading above its key moving averages, which is a strong confirmation that the underlying uptrend remains intact. Specifically, the 20-day Simple Moving Average (SMA) at $25.65 is acting as immediate dynamic support for the stock.
What This Means for Traders?
As long as PFE continues to hold above the 20-day SMA ($25.65), the bullish momentum could certainly persist. However, a rapid rise can often push the stock too far from its averages, which naturally increases the risk of a potential pullback or correction.
Momentum Check – Is Pfizer’s Momentum Fading?
The Relative Strength Index (RSI) for PFE stands at 52.0, placing it squarely in a neutral zone. This indicates a balanced momentum—neither overbought nor oversold. Simultaneously, the MACD histogram is showing negative readings, which often suggests that the upward momentum is beginning to lose some of its steam.
Trading Strategy:
This neutral RSI reading offers a degree of flexibility. For the next directional clue, traders should keep a close eye on a decisive MACD crossover or a clear break of a significant support or resistance level.
Bollinger Bands – PFE Testing Key Levels
Pfizer’s stock is currently pressing against the upper Bollinger Band at $26.23. This level frequently acts as a short-term resistance point, where price advances might pause or reverse.
Key Levels to Watch:
- Resistance: The recent high of $26.48 is a critical resistance point. A confirmed breakout above this level could potentially push PFE higher.
- Support: The 20-day SMA at $25.65 is immediate support. If this level breaks, expect a test of $25.06.
Volume Trends – Checking for Conviction in PFE
Trading volume for Pfizer is currently near its recent average. This provides neutral confirmation of the current price action, meaning there isn’t an overwhelming surge of buying or selling conviction driving the stock’s recent movements.
Support & Resistance – The PFE Trading Plan
- ✅ If PFE holds above $25.65: The bullish trend is likely to continue, with the next target being $26.48.
- ⚠️ If it breaks below $25.65: Expect a potential dip toward the $25.06 level.
- 🛑 A drop below $25.06: This could trigger a deeper correction, potentially bringing the price down to the 200-day SMA at $24.28.
Final Verdict – Should You Buy, Hold, or Sell PFE?
Short-Term Traders:
The trend is positive, but it’s crucial to monitor for signs of exhaustion. A neutral stance might be the most prudent approach until a clearer signal emerges from the MACD or volume indicators. Be ready to react swiftly to changes.
Long-Term Investors:
The long-term uptrend for PFE remains valid as long as the price holds above the 200-day SMA ($24.28). A pullback towards the 50-day SMA ($25.03) area could present a safer and more attractive buying opportunity for those looking to accumulate shares.
New Buyers:
It’s generally advisable to avoid chasing the current rally. Instead, consider waiting for either a confirmed breakout above $26.48 with strong volume, or a more favorable pullback to the $25.65 area, which would offer a better risk/reward entry point.
Bottom Line:
The technical analysis suggests that Pfizer’s rally might be running out of short-term steam. While the long-term trend remains bullish, a temporary correction seems plausible before the next significant move. Trade carefully and patiently wait for clear confirmations at these key technical levels.
PFE Historical Performance: Recent Trading Data
Looking at Pfizer’s recent trading activity, from November 28, 2025, to December 12, 2025, the stock delivered a modest total return of +0.43%. During this period, the price moved between a high of $26.19 and a low of $25.04, indicating some daily fluctuations. The average daily trading volume during this timeframe was approximately 41,183,534 shares, suggesting consistent investor interest.
Recent Trading Data for Pfizer Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| 2025-12-12 | $25.83 | $26.04 | $25.72 | $25.85 | 51,039,612 |
| 2025-12-11 | $25.80 | $26.04 | $25.61 | $25.80 | 35,570,200 |
| 2025-12-10 | $25.49 | $25.79 | $25.22 | $25.78 | 43,635,400 |
| 2025-12-09 | $26.00 | $26.13 | $25.13 | $25.33 | 43,483,800 |
| 2025-12-08 | $26.04 | $26.19 | $25.76 | $25.77 | 45,209,300 |
| 2025-12-07 | $25.77 | $26.12 | $25.64 | $26.03 | 47,443,700 |
| 2025-12-06 | $25.77 | $26.12 | $25.64 | $26.03 | 47,443,700 |
| 2025-12-05 | $25.77 | $26.12 | $25.64 | $26.03 | 47,443,700 |
| 2025-12-04 | $25.63 | $25.74 | $25.35 | $25.70 | 35,454,000 |
| 2025-12-03 | $25.32 | $25.89 | $25.30 | $25.57 | 56,121,200 |
| 2025-12-02 | $25.32 | $25.32 | $25.04 | $25.15 | 43,827,000 |
| 2025-12-01 | $25.76 | $25.94 | $25.23 | $25.27 | 53,198,600 |
| 2025-11-30 | $25.85 | $25.86 | $25.66 | $25.74 | 22,627,600 |
| 2025-11-29 | $25.85 | $25.86 | $25.66 | $25.74 | 22,627,600 |
| 2025-11-28 | $25.85 | $25.86 | $25.66 | $25.74 | 22,627,600 |
PFE Stock Price Statistics: Volatility and Market Sensitivity
When examining Pfizer’s stock price statistics, we see that over the past year, the stock has traded within a range of $20.92 to $27.69. This moderate gap indicates that PFE has experienced notable price swings, reflecting dynamic investor sentiment. Currently, the 50-day moving average at $25.17 is slightly above the 200-day moving average of $24.54. This configuration, often referred to as a ‘golden cross,’ is typically viewed as a bullish signal, indicating positive long-term momentum for the stock.
With a Beta of 0.42x, Pfizer’s stock tends to be less volatile than the broader market, moving about 58% less. This lower sensitivity can be appealing to investors seeking a more stable asset. However, when combined with a moderate 30-day annualized volatility of 20.3%, it’s clear that PFE still experiences frequent price swings. For investors, this translates to potential opportunities for gains, but also an inherent level of downside risk. These indicators are crucial when deciding on position sizing or entry timing, especially if you’re managing a portfolio that aims to balance stability with growth exposure.
| Metric | Value |
|---|---|
| 52 Week High | $27.69 |
| 52 Week Low | $20.92 |
| 50 Day MA | $25.17 |
| 200 Day MA | $24.54 |
| Beta | 0.42x |
| Volatility (30d Ann.) | 20.3% |
Pfizer’s Quarterly Earnings Performance
Pfizer’s recent quarterly performance provides an important snapshot of the company’s operational and financial trajectory. In its latest reported quarter (2025-Q3), Pfizer recorded revenue of $16.65 billion and a net income of $3.54 billion. These figures give us a baseline for evaluating its short-term results.
Comparing performance, the quarter-over-quarter revenue change showed a positive increase of +13.7%. However, the year-over-year revenue growth stands at -5.9%, indicating that while there was recent sequential improvement, the company is still facing headwinds when compared to its performance a year ago. This mixed picture highlights the challenges and opportunities Pfizer is navigating.
Recent Quarterly Results (Last 4 Quarters)
| Quarter | Revenue | Net Income | EPS | Gross Margin |
|---|---|---|---|---|
| 2025-Q3 | $16.65 B | $3.54 B | 0.62x | 74.9% |
| 2025-Q2 | $14.65 B | $2.91 B | 0.51x | 74.2% |
| 2025-Q1 | $13.71 B | $2.97 B | 0.52x | 79.3% |
| 2024-Q4 | $17.76 B | $410.00 M | 0.07x | 66.7% |
Growth Metrics
| Metric | Value |
|---|---|
| QoQ Revenue Growth | +13.7% |
| QoQ Net Income Growth | +21.7% |
| YoY Revenue Growth | -5.9% |
PFE Short Selling Information: Understanding Bearish Sentiment
Let’s take a look at the short interest surrounding Pfizer (PFE) to gauge bearish sentiment. Currently, there are 139 million shares sold short, and the short ratio, or “days to cover,” stands at 1.5x. What this means is that, based on the stock’s recent average trading volume, it would take approximately two days for all short positions to be covered. This relatively low level of days to cover suggests that short sellers do not currently exert significant control over the stock’s price, and the risk of a prolonged ‘short squeeze’ (where a rapid rise in price forces short sellers to buy back shares, further fueling the rally) is relatively low.
With 2.45% of the public float sold short, a moderate percentage of the stock is being shorted. This indicates some bearish sentiment, but it’s far from an extreme level. Interestingly, this level has recently increased from 127 million shares, suggesting a slight shift towards more bearish views among some investors. However, because the overall amount of investors betting against the stock is generally low, the market tends to feel more confident.
This reduces the risks of dramatic price swings that can often occur from sudden short-covering activities. For real-time short interest data, platforms like MarketWatch can be useful.
| Metric | Value |
|---|---|
| Shares Short | 139 M |
| Short Ratio (Days To Cover) | 1.50x |
| Short % of Float | 2.45% |
| Shares Short (Prior Month) | 127 M |
| Short Date | 2025-11-28 |
PFE Risk Analysis: Navigating Potential Headwinds
Investing in Pfizer (PFE) comes with its share of risks, as with any stock. Understanding these potential factors, identified through data analysis and general market considerations, is crucial for any investor. Pfizer’s risk profile reveals moderate volatility, with an annualized volatility of 19.8%. This indicates a moderate level of investment risk, meaning the stock experiences noticeable, but not extreme, price fluctuations.
The Sharpe ratio of 0.10x suggests mixed risk-adjusted returns, indicating that for the level of risk taken, the returns have not been exceptionally high. Furthermore, the maximum drawdown of -58.96% is a significant figure, highlighting that the stock has experienced substantial downside risk during adverse market conditions in the past. This historical data point is a stark reminder of potential capital loss.
On the quantitative risk front, the Value at Risk (VaR) at a 5% confidence level shows a potential loss of -1.90% in the worst 5% of scenarios. This gives investors an idea of the maximum expected loss over a specific timeframe under normal market conditions. Additionally, the Sortino ratio of 0.14x provides further insight by focusing specifically on downside risk, evaluating returns only against harmful volatility. Investors should always consider these risk metrics in conjunction with their own risk tolerance and overall investment objectives.
| Metric | Value |
|---|---|
| Volatility (Annualized) | 19.8% |
| Value at Risk (5%) | -1.90% |
| Value at Risk (1%) | -3.49% |
| Sharpe Ratio | 0.10x |
| Sortino Ratio | 0.14x |
| Maximum Drawdown | -58.96% |
| Skewness | 0.39x |
| Kurtosis | 8.25x |
PFE Sentiment Analysis: Gauging Market Mood for Pfizer
Current market sentiment analysis for Pfizer (PFE) reveals a cautiously positive outlook. The composite sentiment score stands at 0.28x, coupled with a confidence level of 49.3%. This overall positive sentiment is derived from a variety of data sources, including recent news coverage, analyst recommendations, and activity within the options market.
Breaking down these sentiment components provides a clearer picture. News analysis shows a Positive sentiment score of 0.17x, indicating that recent headlines and media coverage have generally been favorable. Analyst consensus is even stronger, reflecting a Positive sentiment score of 0.40x, which suggests that Wall Street professionals are largely optimistic about Pfizer’s prospects. Finally, options market sentiment also reflects a Positive score of 0.18x, where trading activity in puts and calls points towards bullish expectations. These sentiment indicators, while valuable, should always be considered alongside fundamental and technical analysis for a truly comprehensive investment perspective.
| Metric | Value |
|---|---|
| Composite Sentiment Score | 0.28x |
| Sentiment Classification | Positive |
| Sentiment Confidence | 49.3% |
| News Sentiment | Positive (0.17x) |
| Analyst Sentiment | Positive (0.40x) |
| Options Sentiment | Positive (0.18x) |
| Put/Call Ratio | 0.41x |
PFE Peer Comparison: Pfizer Against Industry Giants
To truly understand Pfizer’s position, it’s helpful to compare it against some of its major peers in the pharmaceutical industry: Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), and Merck & Co., Inc. (MRK). Pfizer’s $146.98 billion market cap positions it as the smallest among these giants, with LLY at $921.12 billion, JNJ at $509.76 billion, and MRK at $250.53 billion.
When it comes to valuation, Pfizer’s conservative P/E ratio of 15.03x suggests a more value-oriented pricing, while Eli Lilly (P/E 50.24x) trades at significantly higher premium multiples, indicative of strong growth expectations. Merck (P/E 13.27x), in contrast, trades at much lower multiples, often reflecting a more mature or slower-growth business profile. In terms of revenue, Pfizer experienced a decline of -5.90%, whereas Eli Lilly showcased impressive momentum with 53.90% revenue growth. Despite revenue challenges, Pfizer demonstrates strong profitability with a robust 15.65% net margin, compared to LLY (30.99%) and JNJ (27.26%).
Pfizer’s solid 10.60% Return on Equity (ROE) highlights good capital efficiency. With a 66.53% debt-to-equity ratio, Pfizer maintains moderate leverage, while Eli Lilly (179%) shows even higher leverage. Finally, Pfizer’s attractive 6.65% dividend yield provides substantial income to shareholders, a significant point of comparison against LLY (61.00%) and JNJ (2.46%), though LLY’s high yield likely reflects a special dividend or specific payout structure. These comparisons provide critical context for assessing Pfizer’s relative strengths and weaknesses within a competitive landscape.
| Metric | PFE | LLY | JNJ | MRK |
|---|---|---|---|---|
| Market Cap | $146.98B | $921.12B | $509.76B | $250.53B |
| P/E Ratio | 15.03 | 50.24 | 20.44 | 13.27 |
| Revenue Growth | -5.90% | 53.90% | 6.80% | 3.70% |
| Net Margin | 15.65% | 30.99% | 27.26% | 29.63% |
| EPS | 1.72 | 20.45 | 10.35 | 7.56 |
| ROE | 10.60% | 96.47% | 33.62% | 39.49% |
| Debt-to-Equity | 66.53 | 179 | 57.77 | 79.71 |
| Dividend Yield | 6.65% | 61.00% | 2.46% | 3.39% |
| 52-Week Range | 19.83 – 27.21 | 621.50 – 1111.99 | 136.50 – 212.27 | 71.87 – 105.84 |
PFE Insider Transactions (Last 3 Months)
Over the last three months, Pfizer’s insider activity shows a total of 12 transactions. It’s important to note that a significant portion—all 12 of these transactions—were related to stock awards or tax-related dispositions. These are typically compensation-related activities rather than discretionary market buys or sells by insiders. This predominance of award-related transactions suggests that this is routine equity compensation, rather than a strong directional signal about the company’s future prospects. Essentially, it doesn’t necessarily indicate a bullish or bearish stance from insiders based on their market outlook.
| Insider Name | Type | Shares Changed | Price | Shares After | Transaction Date | Filing Date |
|---|---|---|---|---|---|---|
| BOURLA ALBERT | BUY (Award) [A] | +23 | $25.74 | 743,115 | 2025-11-28 | 2025-12-02 |
| BOURLA ALBERT | BUY (Award) [A] | +24 | $25.06 | 743,548 | 2025-11-14 | 2025-11-17 |
| BOURLA ALBERT | BUY (Award) [A] | +24 | $24.65 | 731,108 | 2025-10-31 | 2025-11-03 |
| BOURLA ALBERT | BUY (Award) [A] | +25 | $24.39 | 731,111 | 2025-10-15 | 2025-10-17 |
| BOURLA ALBERT | BUY (Award) [A] | +83 | $24.52 | 731,058 | 2025-10-14 | 2025-10-16 |
| Echevarria Joseph | BUY (Award) [A] | +1,815 | $25.48 | 144,990 | 2025-09-30 | 2025-10-02 |
| SMITH JAMES C | BUY (Award) [A] | +1,766 | $25.48 | 161,563 | 2025-09-30 | 2025-10-02 |
| BOURLA ALBERT | BUY (Award) [A] | +24 | $25.48 | 730,773 | 2025-09-30 | 2025-10-02 |
| Quincey James | BUY (Award) [A] | +1,521 | $25.48 | 71,917 | 2025-09-30 | 2025-10-02 |
| Taraporevala Cyrus | BUY (Award) [A] | +1,472 | $25.48 | 23,445 | 2025-09-30 | 2025-10-02 |
| NARAYEN SHANTANU | BUY (Award) [A] | +1,962 | $25.48 | 178,125 | 2025-09-30 | 2025-10-02 |
| BOURLA ALBERT | BUY (Award) [A] | +25 | $23.97 | 730,907 | 2025-09-15 | 2025-09-17 |
PFE Risk Factors: Key Challenges for Pfizer Investors
Investing in Pfizer (PFE) involves various risks that of. This section outlines potential factors identified through a combination of data analysis and general market considerations. It’s important to remember that this list is not exhaustive, and new risks can always emerge.
- ⚠️ Negative Year-over-Year Revenue Growth: The -5.90% decline in year-over-year revenue growth poses a significant risk to future financial performance and could impact investor confidence.
- ⚠️ Negative Year-over-Year Earnings Growth: A substantial -21.30% decline in year-over-year earnings growth raises concerns about profitability trends and the company’s ability to convert revenue into bottom-line results.
- ⚠️ General Market Fluctuations: Like all stocks, PFE is susceptible to broader market fluctuations and changes in overall economic conditions, especially within the sensitive Healthcare sector.
PFE Analyst Insights and Consensus
What are Wall Street analysts saying about Pfizer (PFE)? The general consensus among professionals is quite positive, with an average recommendation of ‘Buy’. This strong sentiment is based on the opinions from 24 analysts who actively cover the stock. Their average target price for PFE is $28.91, with a range spanning from a low of $24.00 to a high of $36.16.
This average target suggests a potential upside of approximately 11.8% compared to the current price of $25.85. This reflects an overall optimistic outlook from the analyst community regarding Pfizer’s future prospects.
| Metric | Value |
|---|---|
| Recommendation | Buy |
| Mean Target Price | $28.91 |
| High Target Price | $36.16 |
| Low Target Price | $24.00 |
| Number of Analyst Opinions | 24 |
Recent News and Developments Affecting PFE
Staying updated on recent headlines related to Pfizer (PFE) is key to understanding current market sentiment and potential catalysts. Here’s a summary of some of the latest news and relevant industry developments:
- Forget Teladoc and Buy This Healthcare Stock Instead (Publisher: Motley Fool, Published: 2025-12-13T12:13:00Z)
- Pfizer Is Still Struggling to Replace Its COVID Revenue. Here’s What We Could See From the Pharmaceutical Giant in 2026. (Publisher: Motley Fool, Published: 2025-12-12T16:52:00Z)
- Eli Lilly’s Next-Generation Obesity Drug Secures First Phase III Win (Publisher: Zacks, Published: 2025-12-12T16:17:00Z)
- The Best Turnaround Stock to Invest $1,000 in Right Now (Publisher: Motley Fool, Published: 2025-12-12T15:35:00Z)
- Moderna Sounds the Alarm: Is China About to Seize the Biotech Crown from the U.S.? (Publisher: GuruFocus.com, Published: 2025-12-11T19:03:40Z)
PFE Conclusion and Investment Outlook
So, where does Pfizer Inc. (PFE) stand as an investment opportunity right now? Let’s recap its performance and outlook.
Short-Term Technical Snapshot
| Metric | Observation |
|---|---|
| Overall Technical Sentiment | ● Neutral |
| Price Trend vs MAs | ▲ Bullish (above SMA50/200) |
| Momentum (RSI) | ● Neutral (52.0) |
| Support / Resistance (30d) | ~$24.28 / ~$26.48 |
Longer-Term Fundamental & Forecast Outlook
| Metric | Observation |
|---|---|
| 1-Year Avg. Forecast (Model) | ▼ ~-9.2% average change to ≈$23.48 |
| Valuation Snapshot | ➕ Potentially Attractive (Fwd P/E: 8.44x) |
| Recent Growth (YoY) | ➖ Negative (Revenue: -5.90%, Earnings: -21.30%) |
| Analyst Consensus | ▲ Buy (Target: $28.91) |
Overall Assessment & Outlook for Pfizer Inc.
Overall, Pfizer (PFE) presents a complex picture. Technically, the stock appears neutral, despite trading above its key moving averages, with a neutral RSI suggesting a pause in momentum. Fundamentally, while some aspects of its financial health appear robust (like ROE and a manageable debt-to-equity ratio), the negative year-over-year revenue and earnings growth are significant concerns. From a valuation standpoint, the forward P/E of 8.44x could be seen as potentially attractive, hinting at expected earnings recovery.
However, model forecasts project a potential 1-year downside of -9.2%, targeting approximately $23.48. This contrasts with the more optimistic analyst consensus of a ‘Buy’ recommendation and an average target of $28.91. Investors must carefully weigh these divergent views against the identified risks specific to Pfizer, such as declining revenue and earnings, and consider their individual investment horizon. It’s a stock that demands careful consideration and a clear understanding of both its strengths and challenges.
Frequently Asked Questions About PFE Stock
What is the PFE stock price prediction for the next year (2025-2026)?
Based on current models, the average 1-year price forecast for PFE is approximately $23.48. This represents a potential -9.2% change from the recent price of $25.85. It’s crucial to remember that this is a model-driven estimate, not a guarantee, and actual prices will fluctuate significantly based on numerous market factors and company developments.
Will PFE stock go up or down?
The 1-year forecast model suggests that the price might decrease moderately on average (a potential -9.2%). However, the short-term direction is highly uncertain and heavily influenced by prevailing market sentiment (currently ‘Neutral’), breaking news, and overall economic conditions. Technical indicators, such as the neutral RSI (52.0), provide clues for near-term direction, but no definitive answer.
Is PFE stock a good investment right now?
Determining if PFE is a ‘good buy’ right now involves balancing various elements: ‘Neutral’ technicals, a model-driven forecast of -9.2% potential downside, and an analyst consensus of +11.8% upside. Technically, the RSI indicates neutral conditions (RSI: 52.0), suggesting balanced momentum. While the company has an attractive forward P/E, three potentially significant risk factors specific to PFE were identified (negative revenue and earnings growth, general market fluctuations). You should weigh these factors against your own investment goals and risk profile. This report is for informational purposes; always consult a financial advisor before investing.
How volatile is PFE stock?
Based on the recent 30-day price action, PFE’s annualized volatility is approximately 20.3%. This level is currently considered moderate, indicating a noticeable degree of recent price fluctuation. This aligns with its Beta of 0.42x, meaning it tends to be less volatile than the broader market. Higher volatility means larger potential price swings, both upwards and downwards.
What is PFE’s P/E ratio and what does it mean?
PFE’s Trailing P/E ratio (based on past earnings) is 15.03x, which is considered moderate. Its Forward P/E (based on expected earnings) is 8.44x. A P/E ratio indicates how much investors are paying per dollar of earnings. A lower forward P/E compared to trailing suggests expectations of higher future earnings. You should compare these ratios to industry peers and historical levels to gauge whether the stock is undervalued or overvalued.
What are the key upcoming events for PFE?
A key upcoming event for income investors is the ex-dividend date on 2026-01-23. Beyond this, analysts and investors should monitor macroeconomic shifts, competitive actions within the pharmaceutical industry, and any major corporate announcements regarding pipeline developments, clinical trial results, or strategic partnerships.
What does PFE’s liquidity position reveal about its financial health?
PFE’s financial health includes an adequate Current Ratio of 1.28x, indicating it can cover its short-term liabilities. However, its robust operating cash flow of $13.08 billion and levered free cash flow of $14.30 billion provide a significant buffer. These strong cash flow metrics are critical factors in its ability to fund operations, manage debt, and return capital to shareholders, showcasing a solid liquidity position despite some efficiency challenges.